MARKET

BAX

BAX

Baxter Intl
NYSE

Real-time Quotes | Nasdaq Last Sale

76.32
+0.22
+0.28%
After Hours: 76.32 0 0.00% 17:22 12/03 EST
OPEN
75.53
PREV CLOSE
76.11
HIGH
76.52
LOW
75.38
VOLUME
5.42M
TURNOVER
--
52 WEEK HIGH
95.19
52 WEEK LOW
69.10
MARKET CAP
38.99B
P/E (TTM)
54.15
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Baxter and AdventHealth Tampa Announce Cost Savings Achieved Through Intraoperative Hemostasis Management Program
Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, and AdventHealth Tampa today announced that AdventHealth Tampa will realize approximately $200,000 in annual savings through its involvement in Baxter's Vital Edge program. Vital Edge is a data-driven, evidence-based intraoperative hemostasis management program designed to help hospitals and health care providers improve hemostasis utilization practices impacting three interconnected areas of surgical care: clinical efficacy, operational efficiency and financial performance.
BusinessWire · 13h ago
Global Conventional and Alternative Pain Treatment Markets Report 2020-2025 with Profiles of Abbott Laboratories, Baxter International, Eli Lilly & Co., GlaxoSmithKline, and Johnson & Johnson
, /PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 1d ago
The Top 5 Trades of the MS Global Franchise Fund
Fund reveals 3rd-quarter portfolio
GuruFocus.com · 2d ago
Baxter (BAX) Announces Site Expansion to Improve Patient Care
Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
Zacks · 3d ago
There's A Lot To Like About Baxter International's (NYSE:BAX) Upcoming US$0.24 Dividend
Simply Wall St. · 5d ago
Is Baxter International Inc. (NYSE:BAX) Expensive For A Reason? A Look At Its Intrinsic Value
Does the November share price for Baxter International Inc. (NYSE:BAX) reflect what it's really worth? Today, we will...
Simply Wall St. · 6d ago
Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System
Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
Zacks · 11/26 12:15
Worldwide Clinical Nutrition Industry to 2025 - Key Drivers and Challenges
, /PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 11/25 15:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BAX. Analyze the recent business situations of Baxter Intl through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BAX stock price target is 94.35 with a high estimate of 105.00 and a low estimate of 84.00.
EPS
Institutional Holdings
Institutions: 1.51K
Institutional Holdings: 456.06M
% Owned: 89.28%
Shares Outstanding: 510.82M
TypeInstitutionsShares
Increased
335
28.11M
New
178
-1.18M
Decreased
407
30.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.85%
Healthcare Equipment & Supplies
-1.15%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jose Almeida
Chief Financial Officer/Executive Vice President
James Saccaro
Senior Vice President/Chief Accounting Officer/Controller
Brian Stevens
Senior Vice President/General Counsel
Sean Martin
Senior Vice President/Director of Human Resources
Jeanne Mason
Senior Vice President
Giuseppe Accogli
Senior Vice President
Cristiano Franzi
Senior Vice President
Andrew Frye
Senior Vice President
Jacqueline Kunzler
Lead Director/Independent Director
Thomas Stallkamp
Independent Director
Thomas Chen
Independent Director
John Forsyth
Independent Director
James Gavin
Independent Director
Peter Hellman
Independent Director
Michael Mahoney
Independent Director
Patricia Morrison
Independent Director
Stephen Oesterle
Independent Director
Cathy Smith
Independent Director
Albert Stroucken
Independent Director
Amy Wendell
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
11/16/2020
Dividend USD 0.245
12/03/2020
07/14/2020
Dividend USD 0.245
08/28/2020
05/05/2020
Dividend USD 0.245
06/04/2020
02/18/2020
Dividend USD 0.22
02/27/2020
11/19/2019
Dividend USD 0.22
12/05/2019
07/16/2019
Dividend USD 0.22
08/29/2019
05/07/2019
Dividend USD 0.22
06/06/2019
02/19/2019
Dividend USD 0.19
02/28/2019
11/13/2018
Dividend USD 0.19
11/30/2018
07/17/2018
Dividend USD 0.19
08/30/2018
05/08/2018
Dividend USD 0.19
05/31/2018
02/20/2018
Dividend USD 0.16
03/01/2018
11/14/2017
Dividend USD 0.16
11/30/2017
07/18/2017
Dividend USD 0.16
08/30/2017
05/02/2017
Dividend USD 0.16
05/31/2017
02/21/2017
Dividend USD 0.13
03/01/2017
11/08/2016
Dividend USD 0.13
11/30/2016
07/19/2016
Dividend USD 0.13
08/31/2016
05/03/2016
Dividend USD 0.13
06/01/2016
02/16/2016
Dividend USD 0.115
03/02/2016
11/10/2015
Dividend USD 0.115
12/02/2015
07/30/2015
Dividend USD 0.115
09/02/2015
05/05/2015
Dividend USD 0.52
05/28/2015
02/17/2015
Dividend USD 0.52
03/09/2015
11/11/2014
Dividend USD 0.52
12/03/2014
07/22/2014
Dividend USD 0.52
09/03/2014
05/05/2014
Dividend USD 0.52
06/04/2014
02/18/2014
Dividend USD 0.49
03/05/2014
11/12/2013
Dividend USD 0.49
12/04/2013
07/24/2013
Dividend USD 0.49
09/04/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BAX
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Baxter International Inc stock information, including NYSE:BAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BAX stock methods without spending real money on the virtual paper trading platform.